The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Gabrene     4-[[(E)-(4-chlorophenyl)-(3- fluoro-6-oxo-1...

Synonyms: Progabida, Progabide, Gabren, Halogabide, Progabidum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Progabide


Psychiatry related information on Progabide


High impact information on Progabide


Chemical compound and disease context of Progabide


Biological context of Progabide


Anatomical context of Progabide

  • Similarly, the brain extraction of the drugs in the presence of either albumin, or red blood cells for progabide was inversely related to their respective concentrations [20].
  • Thus, after i.p. administration of 100 mg/kg progabide, a significant increase in seizure latency and significant decreases in duration of motor seizures and amygdala afterdischarges were determined [19].
  • Repeated progabide and valproate (but not diazepam) administration attenuated the sedation response to the alpha 2-adrenoceptor agonist, clonidine (0.15 mg kg-1) but neither drug altered beta-adrenoceptor number in the cerebral cortex [16].
  • Furthermore, since systemically administered progabide still increased hypothalamic DOPEG levels after ibotenate-induced destruction of the hypothalamic neuronal cell bodies, a presynaptic modulation of noradrenergic neurons by local GABAergic interneurons is excluded [22].
  • Determination of progabide and its main acid metabolite in biological fluids using high-performance liquid chromatography and electrochemical detection. Application to the measurement of blood/plasma partition ratio [23].

Associations of Progabide with other chemical compounds


Gene context of Progabide


Analytical, diagnostic and therapeutic context of Progabide

  • Progabide does not seem to be the drug urgently needed for failures of previous high-dose drug therapy [29].
  • The monoaminergic changes induced by progabide, though dissimilar from those induced by tricyclics, are probably connected with the antidepressant action on the compound observed in double-blind clinical trials [3].
  • These data confirm the anticonvulsant properties of progabide in another animal model [31].
  • At the same time intervals, safety was assessed by means of reports of adverse events, clinical and neurological examination, laboratory tests, and measurement of plasma concentrations of progabide and associated AEDs [32].
  • Intravenous injection of various doses (30 to 100 mg/kg) of progabide induced a protective effect against intermittent light stimulation (25 Hz) in both test situations [31].


  1. Progabide in Parkinson's disease. Luquin, M.R., Obeso, J.A., Scatton, B., Lheroux, A., Martinez Lage, J.M. Ann. Neurol. (1987) [Pubmed]
  2. The GABA-agonist progabide for spasticity in multiple sclerosis. Rudick, R.A., Breton, D., Krall, R.L. Arch. Neurol. (1987) [Pubmed]
  3. Pharmacology of the GABAergic system: effects of progabide, a GABA receptor agonist. Bartholini, G. Psychoneuroendocrinology (1984) [Pubmed]
  4. Progabide: a controlled trial in partial epilepsy. Dam, M., Gram, L., Philbert, A., Hansen, B.S., Lyon, B.B., Christensen, J.M., Angelo, H.R. Epilepsia (1983) [Pubmed]
  5. Double-blind crossover trial of progabide versus placebo in severe epilepsies. Loiseau, P., Bossi, L., Guyot, M., Orofiamma, B., Morselli, P.L. Epilepsia (1983) [Pubmed]
  6. Effects of gamma-aminobutyric acid (GABA) receptor agonists on the neurotoxicity and anticonvulsant activity of barbiturates in mice. Ulloque, R.A., Chweh, A.Y., Swinyard, E.A. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  7. GABAergic drugs and sexual motivation, receptivity and exploratory behaviors in the female rat. Agmo, A., Soria, P. Psychopharmacology (Berl.) (1997) [Pubmed]
  8. The effects of progabide (SL 76002) on locomotor activity and conditioned place preference induced by d-amphetamine. Di Scala, G., Martin-Iverson, M.T., Phillips, A.G., Fibiger, H.C. Eur. J. Pharmacol. (1985) [Pubmed]
  9. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Lloyd, K.G., Morselli, P.L., Depoortere, H., Fournier, V., Zivkovic, B., Scatton, B., Broekkamp, C., Worms, P., Bartholini, G. Pharmacol. Biochem. Behav. (1983) [Pubmed]
  10. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Kroetz, D.L., Loiseau, P., Guyot, M., Levy, R.H. Clin. Pharmacol. Ther. (1993) [Pubmed]
  11. GABA receptor agonists: pharmacological spectrum and therapeutic actions. Bartholini, G. Medicinal research reviews. (1985) [Pubmed]
  12. Postnatal evolution of the gamma-aminobutyric acid/benzodiazepine receptor complex in a model of inherited epilepsy: the quaking mouse. Caboche, J., Mitrovic, N., Le Saux, F., Besson, M.J., Sauter, A., Maurin, Y. J. Neurochem. (1989) [Pubmed]
  13. The inhibitory effects on sexual behavior and ambulatory activity of the mixed GABAA/GABAB agonist progabide are differentially blocked by GABA receptor antagonists. Agmo, A., Paredes, R.G., Sierra, L., Garcés, I. Psychopharmacology (Berl.) (1997) [Pubmed]
  14. Chlordiazepoxide-induced hyperphagia in rats: lack of effect of GABA agonists and antagonists. Sanger, D.J. Psychopharmacology (Berl.) (1984) [Pubmed]
  15. A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy. Crawford, P., Chadwick, D. J. Neurol. Neurosurg. Psychiatr. (1986) [Pubmed]
  16. Some anticonvulsant drugs alter monoamine-mediated behaviour in mice in ways similar to electroconvulsive shock; implications for antidepressant therapy. Green, A.R., Johnson, P., Mountford, J.A., Nimgaonkar, V.L. Br. J. Pharmacol. (1985) [Pubmed]
  17. Differential effects of the benzodiazepine antagonist Ro 15-1788 on two types of myoclonus in baboon Papio papio. Valin, A., Kaijima, M., Bryere, P., Naquet, R. Neurosci. Lett. (1983) [Pubmed]
  18. Disposition of progabide and valproic acid following intraperitoneal administration in rhesus monkey. Johno, I., Bialer, M., Nickelson, S.A., Levy, R.H. Epilepsia (1984) [Pubmed]
  19. Evaluation of different GABA receptor agonists in the kindled amygdala seizure model in rats. Löscher, W., Schwark, W.S. Exp. Neurol. (1985) [Pubmed]
  20. Effect of erythrocytes and plasma protein binding on the transport of progabide and SL 75102 through the rat blood-brain barrier. Hamberger, C., Urien, S., Essassi, D., Grimaldi, B., Barre, J., Taiclet, A., Thenot, J.P., Tillement, J.P. Biochem. Pharmacol. (1987) [Pubmed]
  21. The stability and solubility of progabide and its related metabolic derivatives. Farraj, N.F., Davis, S.S., Parr, G.D., Stevens, H.N. Pharm. Res. (1988) [Pubmed]
  22. Further evidence for, and nature of, the facilitatory GABAergic influence on central noradrenergic transmission. Dennis, T., Curet, O., Nishikawa, T., Scatton, B. Naunyn Schmiedebergs Arch. Pharmacol. (1985) [Pubmed]
  23. Determination of progabide and its main acid metabolite in biological fluids using high-performance liquid chromatography and electrochemical detection. Application to the measurement of blood/plasma partition ratio. Padovani, P., Deves, C., Bianchetti, G., Thenot, J.P., Morselli, P.L. J. Chromatogr. (1984) [Pubmed]
  24. The comparative effects of benzodiazepines, progabide and PK 9084 on acquisition of passive avoidance in mice. Broekkamp, C.L., Le Pichon, M., Lloyd, K.G. Psychopharmacology (Berl.) (1984) [Pubmed]
  25. GABAB-receptor mediated inhibition of potassium-evoked release of endogenous 5-hydroxytryptamine from mouse frontal cortex. Gray, J.A., Green, A.R. Br. J. Pharmacol. (1987) [Pubmed]
  26. Effects in man of progabide on prolactin release induced by haloperidol or domperidone. Menon, V.J., Butt, W.R., Thiercelin, J.F., Gomeni, R., Morselli, P.L., London, D.R. Psychoneuroendocrinology (1984) [Pubmed]
  27. Enhancing GABAergic transmission reverses the aversive state in rats induced by electrical stimulation of the periaqueductal grey region. Bovier, P., Broekkamp, C.L., Lloyd, K.G. Brain Res. (1982) [Pubmed]
  28. Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Mithani, S., Atmadja, S., Baimbridge, K.G., Fibiger, H.C. Psychopharmacology (Berl.) (1987) [Pubmed]
  29. Progabide for refractory partial epilepsy: a controlled add-on trial. Schmidt, D., Utech, K. Neurology (1986) [Pubmed]
  30. Effect of GABA on basal and vagally mediated gastric acid secretion and hormone release in dogs. Thirlby, R.C., Stevens, M.H., Blair, A.J., Petty, F., Crawford, I.L., Taylor, I.L., Walsh, J.H., Feldman, M. Am. J. Physiol. (1988) [Pubmed]
  31. Action of progabide in the photosensitive baboon, Papio papio. Cepeda, C., Worms, P., Lloyd, K.G., Naquet, R. Epilepsia (1982) [Pubmed]
  32. Progabide treatment in severe epilepsy: a double-blind cross-over trial versus placebo. Martínez-Lage, J.M., Bossi, L., Morales, G., Martínez Vila, E., Orofiamma, B., Viteri, C. Epilepsia (1984) [Pubmed]
WikiGenes - Universities